ETBX-011

AXP000154.1 · Cancer vaccine

Platform
adenovirus (Ad5 [E1-, E2b-])
Targets
CEACAM5
Originator
Etubics
Sponsor
ImmunityBio

Names

NameTypeSource
ETBX-011preferred name, codecurator, ncit
Ad5 CEA Vaccine ambiguoussynonymncit
Adenoviral Vector Ad5-CEA(6D) Vaccine ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 [E1-, E2b-]
Replication
non replicating
Modifications
E1 and E2b regions deleted (replication-defective, reduced late gene expression)
Transgenes
CEA(6D) (carcinoembryonic antigen with a modified CAP1-6D epitope)
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C91373
FDA UNII
RP9RQ0SOM8

Approvals

No regulatory approval recorded.

Clinical trials (20)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04247282Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus InfectionCompletedPhase 1/22020-06-092021-08-2421Head and Neck Cancer; Head and Neck Neoplasms
NCT03563157QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedPhase 1/22018-09-282019-04-212Colorectal Cancer Metastatic; mCRC
NCT03554109QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 22018-092020-060Triple Negative Breast Cancer (TNBC)
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 22018-082019-12-300Metastatic Pancreatic Cancer
NCT03169777QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/22018-082019-010Colorectal Cancer
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/22018-07-172019-04-173Pancreatic Cancer
NCT03574649QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 22018-062018-080Non Small Cell Lung Cancer
NCT03563170QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/22018-05-252019-08-230Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent
NCT03387085QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/22018-03-192020-09-119Triple Negative Breast Cancer
NCT03169738QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/22018-022019-010Non-small Cell Lung Cancer
NCT03384316Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerCompletedPhase 12018-01-312018-05-2211Breast Cancer; Colon Cancer; Lung Cancer; Neoplasms; Prostate Cancer
NCT03387111QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/22018-01-092019-04-174Squamous Cell Carcinoma
NCT03387098QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/22017-12-282018-09-124Pancreatic Cancer
NCT03197571QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Urothelial Carcinoma
NCT03175666QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/22017-122019-010Triple Negative Breast Cancer
NCT03169764QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Head and Neck Squamous Cell Carcinoma
NCT03167177QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Melanoma
NCT03329248QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/22017-11-062018-08-136Pancreatic Cancer
NCT03136406QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/22017-08-112017-11-223Pancreatic Cancer
NCT03127098QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerTerminatedPhase 1/22017-06-262017-12-073Breast Cancer; Colon Cancer; Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Thyroid Cancer
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT01147965QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEACompletedPhase 1/22010-07-162017-05-3143Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancerintervention named: Ad5 CEA Vaccine

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40156838Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection.The oncologist2025cited by trial NCT04247282
PMID 35727629Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.The Journal of clinical investigation2022cited by trial NCT04247282
PMID 33720067The role of the tumor matrix environment in progression of head and neck cancer.Current opinion in oncology2021cited by trial NCT04247282
PMID 31594913A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.The oncologist2020cited by trial NCT03384316

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 26374823The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.Oncotarget2015name in abstract: ETBX-011

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: ETBX-011
ZIABC010972Identification of human tumor-associated antigensDIVISION OF BASIC SCIENCES - NCITSANG, KWONG YOK2009–2016name in abstract: ETBX-011
R43CA186357Development of an Ad5-CEA/Brachyury Vector Approach for Cancer TreatmentETUBICS CORPORATIONJONES, FRANK R.2014–2014name in abstract: ETBX-011

Notes

Ad5 [E1-, E2b-] vector of the Etubics (now ImmunityBio) AdenoVerse-style platform, given subcutaneously; the E2b deletion is intended to allow repeat dosing despite pre-existing Ad5 immunity. Studied alone and in the multi-antigen Tri-Ad5 / 'Triad' regimens, which are combinations and not programs of their own. NCIt preferred name: Ad5 [E1-, E2b-]-CEA(6D) Vaccine.

How to cite

ETBX-011 (AXP000154.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000154.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.